
Opinion|Videos|April 11, 2024
Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
FDA Issues CRL to PET Diagnostic Imaging Kit for Gallium-68 Edotreotide in SSTR+ NETs
3
Epcoritamab Plus Lenalidomide Improves PFS vs R-GemOx in R/R DLBCL
4
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
5























































































